FDA expands pirtobrutinib into first-line CLL/SLL for adults without 17p deletion, delivering major PFS gains versus bendamustine-rituximab.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Addressing Disparities in Stem Cell Transplant for Myeloma
2
Evaluating a Virtual Care Navigation Program for Enhanced Oral Oncolytics Management
3
Trials of Bispecifics in Smoldering Myeloma Look Beyond Delaying Progression
4
Opamtistomig Earns FDA Fast Track in First-Line Biliary Tract Cancer
5